Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2018

At a glance

  • Drugs Nivolumab (Primary) ; TG 4010 (Primary) ; Antineoplastics
  • Indications Adenocarcinoma; Carcinoma; Large cell carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Transgene
  • Most Recent Events

    • 21 Sep 2018 Planned End Date changed from 1 May 2020 to 1 Sep 2020.
    • 21 Sep 2018 Planned primary completion date changed from 1 May 2019 to 1 Sep 2019.
    • 19 Sep 2018 According to a Transgene media release, results evaluating primary endpoint are expected in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top